Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Tucidinostat (Primary) ; Paclitaxel; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors HUYA Bioscience International
Most Recent Events
- 14 Jul 2022 Planned End Date changed from 1 Sep 2016 to 2 Dec 2015.
- 14 Jul 2022 Planned primary completion date changed from 1 Jun 2016 to 2 Dec 2015.
- 08 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.